Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (447) 447
Book Review (46) 46
Publication (35) 35
Conference Proceeding (28) 28
Book / eBook (10) 10
Newspaper Article (10) 10
Book Chapter (6) 6
Web Resource (2) 2
Magazine Article (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (281) 281
humans (268) 268
gastroenterology & hepatology (201) 201
male (186) 186
female (185) 185
middle aged (163) 163
adult (151) 151
hepatitis c, chronic - drug therapy (112) 112
antiviral agents - therapeutic use (104) 104
drug therapy, combination (83) 83
hepatitis c (82) 82
hepacivirus - genetics (77) 77
interferon-alpha - therapeutic use (74) 74
recombinant proteins (74) 74
treatment outcome (71) 71
aged (68) 68
ribavirin - therapeutic use (67) 67
abridged index medicus (65) 65
interferon (63) 63
ribavirin (62) 62
gastroenterology and hepatology (58) 58
genotype (58) 58
polyethylene glycols - therapeutic use (54) 54
cirrhosis (53) 53
hepatitis (49) 49
virus-infection (49) 49
plus ribavirin (48) 48
hepatitis c virus (45) 45
therapy (44) 44
antiviral agents - adverse effects (42) 42
antiviral agents - administration & dosage (40) 40
care and treatment (40) 40
rna, viral - blood (40) 40
surgery (39) 39
hepatitis c, chronic - virology (38) 38
transplantation (38) 38
fibrosis (36) 36
liver - pathology (36) 36
prospective studies (36) 36
health aspects (34) 34
risk factors (34) 34
adolescent (33) 33
drug therapy (33) 33
retrospective studies (33) 33
interferon-alpha - administration & dosage (32) 32
alanine transaminase - blood (31) 31
chronic hepatitis-c (31) 31
infection (31) 31
liver (31) 31
ribavirin - administration & dosage (31) 31
combination therapy (30) 30
double-blind method (30) 30
liver transplantation (30) 30
ribavirin - adverse effects (30) 30
article (29) 29
biopsy (29) 29
peginterferon alpha-2a (29) 29
hepacivirus - drug effects (28) 28
liver diseases (28) 28
medicine, general & internal (28) 28
recurrence (28) 28
united-states (28) 28
initial treatment (27) 27
interferon-alpha - adverse effects (27) 27
viral load (27) 27
time factors (26) 26
drug administration schedule (25) 25
hepatitis c, chronic - complications (25) 25
natural-history (25) 25
disease progression (24) 24
hepacivirus - isolation & purification (23) 23
patients (23) 23
young adult (23) 23
clinical trials (22) 22
dose-response relationship, drug (22) 22
follow-up studies (22) 22
hepatology (22) 22
medicine & public health (22) 22
prevalence (22) 22
antiviral agents (21) 21
combination (21) 21
hepatitis c - drug therapy (21) 21
hepatitis c, chronic - pathology (21) 21
liver cirrhosis - virology (21) 21
liver cirrhosis (20) 20
analysis (19) 19
genotype & phenotype (19) 19
liver cirrhosis - pathology (19) 19
peginterferon (19) 19
pharmacology & pharmacy (19) 19
polyethylene glycols - administration & dosage (19) 19
recombinant proteins - therapeutic use (19) 19
trial (19) 19
liver cirrhosis - complications (18) 18
management (18) 18
polyethylene glycols - adverse effects (18) 18
rna (18) 18
disease (17) 17
hepatitis c, chronic - blood (17) 17
infections (17) 17
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Online Resources - Online (1) 1
Robarts - Reference (1) 1
St. Michael's College (John M. Kelly) - Reference (1) 1
St. Michael's Hospital - Online (1) 1
Trinity College (John W Graham) - Reference (1) 1
Trinity College (John W Graham) - Storage (1) 1
UTL at Downsview - May be requested (1) 1
UofT at Scarborough - Stacks (1) 1
Victoria University E.J. Pratt - Reference (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Selected Summary
by Shiffman, Mitchell L
Gastroenterology, ISSN 0016-5085, 01/2018, Volume 154, Issue 1, pp. 253 - 254
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text 131.24JayLefkowitchScheuer’s Liver Biopsy Interpretation, 9th Edition2015ElsevierNew York, New York440ISBN: 9780702055485. Web address for ordering:www.elsevier.com
by Shiffman, Mitchell L
Gastroenterology, ISSN 0016-5085, 01/2018, Volume 154, Issue 1, pp. 253 - 254
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Chronic hepatitis C virus
: advances in treatment, promise for the future
by Shiffman, Mitchell L
2012, ISBN 9781461411925
pathogenicity | Liver Transplantation | therapy | Antiviral Agents | Hepacivirus | therapeutic use | Hepatitis C, Chronic
Web Resource
Details down arrow
4. Hepatology
: a practical approach
by Al Knawy, Bandar and Shiffman, Mitchell L and Wiesner, Russell H
2004, 1st ed., ISBN 9780444513441, xv, 603
Liver -- Diseases
Book
Details down arrow
5. Full Text Print and Digital Media Review
by Shiffman, Mitchell L
Gastroenterology, ISSN 0016-5085, 2014, Volume 146, Issue 2, pp. 583 - 584
Gastroenterology and Hepatology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Response to Perrella et al
by Kwo, Paul Y and Shiffman, Mitchell L and Bernstein, David E
American Journal of Gastroenterology, ISSN 0002-9270, 08/2018, Volume 113, Issue 8, pp. 1251 - 1252
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Financial Compensation For Hepatologists in Different Practice Settings
: Hepatology
by Shiffman, Mitchell L and Sussman, Norman L and Ravendhran, Natarajan and Ditmyer, Macia and Kowdley, Kris V and Kugelmas, Marcelo
Hepatology, ISSN 0270-9139, 06/2019, Volume 69, Issue 6, pp. 2664 - 2671
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Curbside consultation of the liver
by Shiffman, Mitchell L
2008, Curbside consultation in gastroenterology
Liver | Liver Diseases | Diseases
Web Resource
Details down arrow
9. Full Text Diagnosis and Management of Primary Biliary Cholangitis
by Younossi, Zobair M and Bernstein, David and Shiffman, Mitchell L and Kwo, Paul and Kim, W. Ray and Kowdley, Kris V and Jacobson, Ira M
American Journal of Gastroenterology, ISSN 0002-9270, 2018, Volume 114, Issue 1, pp. 48 - 63
Primary biliary cholangitis (PBC) is a chronic, cholestatic, autoimmune disease with a variable progressive course. PBC can cause debilitating symptoms... 
ANTIMITOCHONDRIAL ANTIBODIES | CONTROLLED-TRIAL | HEPATOCELLULAR-CARCINOMA | RISK-FACTORS | LIVER-TRANSPLANTATION | URSODEOXYCHOLIC ACID | SOLUBLE VITAMIN LEVELS | BIOCHEMICAL RESPONSE | CLINICAL-FEATURES | GASTROENTEROLOGY & HEPATOLOGY | PYRUVATE-DEHYDROGENASE COMPLEX
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Managing the Complications of Cirrhosis: A Practical Approach
by Shiffman, Mitchell L
Gastroenterology, ISSN 0016-5085, 2012, Volume 143, Issue 1, pp. 267 - 268
Gastroenterology and Hepatology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Mo1450 - Change in Bilirubin with Obeticholic Acid Treatment in Primary Biliary Cholangitis Patients with High Baseline Bilirubin: A Retrospective Analysis of Poise, 201, and 202
by Hirschfield, Gideon and Shiffman, Mitchell L and Parés, Albert and Malecha, Elizabeth Smoot and Pencek, Richard and MacConell, Leigh and Shapiro, David
Gastroenterology, ISSN 0016-5085, 05/2018, Volume 154, Issue 6, pp. S-1210 - S-1210
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis
: Hepatology
by Trauner, Michael and Gulamhusein, Aliya and Hameed, Bilal and Caldwell, Stephen and Shiffman, Mitchell L and Landis, Charles and Eksteen, Bertus and Agarwal, Kosh and Muir, Andrew and Rushbrook, Simon and Lu, Xiaomin and Xu, Jun and Chuang, Jen-Chieh and Billin, Andrew N and Li, Georgia and Chung, Chuhan and Subramanian, G. Mani and Myers, Robert P and Bowlus, Christopher L and Kowdley, Kris V
Hepatology, ISSN 0270-9139, 03/2019
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
by Poordad, Fred and Hezode, Christophe and Trinh, Roger and Kowdley, Kris V and Zeuzem, Stefan and Agarwal, Kosh and Shiffman, Mitchell L and Wedemeyer, Heiner and Berg, Thomas and Yoshida, Eric M and Forns, Xavier and Lovell, Sandra S and Da Silva-Tillmann, Barbara and Collins, Christine A and Campbell, Andrew L and Podsadecki, Thomas and Bernstein, Barry
The New England Journal of Medicine, ISSN 0028-4793, 05/2014, Volume 370, Issue 21, pp. 1973 - 1982
In patients with HCV genotype 1 infection and cirrhosis, the rate of sustained virologic response was 92% with three new antiviral agents plus ribavirin for 12... 
SUSTAINED VIROLOGICAL RESPONSE | ALL-CAUSE MORTALITY | UNITED-STATES | MEDICINE, GENERAL & INTERNAL | VIRUS-INFECTION | TELAPREVIR | THERAPY | GENOTYPE 1 INFECTION | BOCEPREVIR | HCV INFECTION | EPIDEMIOLOGY | Recurrence | Anilides - therapeutic use | Anilides - adverse effects | Humans | Middle Aged | Drug Resistance, Viral | Hepacivirus - genetics | Male | Hepatitis C, Chronic - complications | Adult | Female | Drug Therapy, Combination | Hepacivirus - isolation & purification | Liver Cirrhosis - drug therapy | Liver Cirrhosis - etiology | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Genotype | Logistic Models | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Complications and side effects | Evaluation | Care and treatment | Usage | Hepatitis C | Liver cirrhosis | Ribavirin | Headache | Antiviral agents | Ritonavir | Body weight | Fatigue | Infections | Nausea | Proteinase inhibitors | RNA polymerase | Patients | Cirrhosis | Liver cancer | Genotype & phenotype | Hepatitis | Hemoglobin | Interferon | Drug therapy | Genotypes | Index Medicus | Abridged Index Medicus | Cirrosi hepàtica | Inhibidors enzimàtics | Enzyme inhibitors | Hepatic cirrhosis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Outcome of sustained virological responders with histologically advanced chronic hepatitis C
by Morgan, Timothy R and Ghany, Marc G and Kim, Hae‐Young and Snow, Kristin K and Shiffman, Mitchell L and De Santo, Jennifer L and Lee, William M and Di Bisceglie, Adrian M and Bonkovsky, Herbert L and Dienstag, Jules L and Morishima, Chihiro and Lindsay, Karen L and Lok, Anna S. F and HALT-C Trial Grp and HALT-C Trial Group and and the HALT-C Trial Group
Hepatology, ISSN 0270-9139, 09/2010, Volume 52, Issue 3, pp. 833 - 844
Retrospective studies suggest that subjects with chronic hepatitis C and advanced fibrosis who achieve a sustained virological response (SVR) have a lower risk... 
FIBROSIS | HEPATOCELLULAR-CARCINOMA | RISK-FACTORS | CIRRHOSIS | FOLLOW-UP | COHORT | GASTROENTEROLOGY & HEPATOLOGY | INTERFERON THERAPY | Recurrence | Carcinoma, Hepatocellular - epidemiology | Liver - pathology | Prognosis | Prospective Studies | Follow-Up Studies | United States | Humans | Middle Aged | Male | Recombinant Proteins | Hepatitis C, Chronic - mortality | Polyethylene Glycols - therapeutic use | Liver Neoplasms - epidemiology | Adult | Female | Severity of Illness Index | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Risk Factors | Interferon-alpha - therapeutic use | Survival Rate | Treatment Outcome | Hepatitis C, Chronic - diagnosis | Hepatitis C, Chronic - drug therapy | Disease Progression | Interferon alpha-2 | Cohort Studies | Hepatitis | Transplants & implants | Liver cirrhosis | Mortality | Index Medicus | hepatitis C treatment | survival analysis | hepatocellular carcinoma | peginterferon
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection
by McHutchison, John G and Lawitz, Eric J and Shiffman, Mitchell L and Muir, Andrew J and Galler, Greg W and McCone, Jonathan and Nyberg, Lisa M and Lee, William M and Ghalib, Reem H and Schiff, Eugene R and Galati, Joseph S and Bacon, Bruce R and Davis, Mitchell N and Mukhopadhyay, Pabak and Koury, Kenneth and Noviello, Stephanie and Pedicone, Lisa D and Brass, Clifford A and Albrecht, Janice K and Sulkowski, Mark S and IDEAL Study Team
The New England Journal of Medicine, ISSN 0028-4793, 08/2009, Volume 361, Issue 6, pp. 580 - 593
In this randomized comparison of treatment with peginterferon alfa-2a, standard-dose peginterferon alfa-2b, and low-dose peginterferon alfa-2b in patients... 
MEDICINE, GENERAL & INTERNAL | PLUS RIBAVIRIN | TREATMENT DURATION | INTERFERON-ALPHA-2B | VIRUS | GENOTYPE-1 PATIENTS | STEATOSIS | COMBINATION THERAPY | RANDOMIZED-TRIAL | INITIAL TREATMENT | Hepacivirus - isolation & purification | Double-Blind Method | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Genotype | Male | RNA, Viral - blood | Recombinant Proteins | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Dose-Response Relationship, Drug | Interferon-alpha - administration & dosage | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Ribavirin - administration & dosage | Female | Interferon-alpha - adverse effects | Drug Therapy, Combination | Hepatitis | Medical research | Liver diseases | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text Erratum: Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir with or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents (American Journal of Gastroenterology 2016; 111:(845-851)) doi: 10.1038/ajg.2016.108
by Shiffman, Mitchell L and Rustgi, Vinod and Bennett, Michael and Forns, Xavier and Asselah, Tarik and Vila, Ramon Planas and Liu, Li and Pedrosa, Marcos and Moller, Jonathan and Reau, Nancy
American Journal of Gastroenterology, ISSN 0002-9270, 07/2016, Volume 111, Issue 7, p. 1077
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Full Text Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection
by Foster, Graham R and Afdhal, Nezam and Roberts, Stuart K and Bräu, Norbert and Gane, Edward J and Pianko, Stephen and Lawitz, Eric and Thompson, Alex and Shiffman, Mitchell L and Cooper, Curtis and Towner, William J and Conway, Brian and Ruane, Peter and Bourlière, Marc and Asselah, Tarik and Berg, Thomas and Zeuzem, Stefan and Rosenberg, William and Agarwal, Kosh and Stedman, Catherine A.M and Mo, Hongmei and Dvory-Sobol, Hadas and Han, Lingling and Wang, Jing and McNally, John and Osinusi, Anu and Brainard, Diana M and McHutchison, John G and Mazzotta, Francesco and Tran, Tram T and Gordon, Stuart C and Patel, Keyur and Reau, Nancy and Mangia, Alessandra and Sulkowski, Mark and ASTRAL-2 & ASTRAL-3 Investigators and ASTRAL-3 Investigators and ASTRAL-2 Investigators
The New England Journal of Medicine, ISSN 0028-4793, 12/2015, Volume 373, Issue 27, pp. 2608 - 2617
In two phase 3 trials involving patients with hepatitis C virus infection, including those with cirrhosis, 12 weeks of sofosbuvir–velpatasvir resulted in a... 
MEDICINE, GENERAL & INTERNAL | C VIRUS-INFECTION | Humans | Middle Aged | Drug Resistance, Viral | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Hepatitis C, Chronic - complications | Young Adult | Heterocyclic Compounds, 4 or More Rings - therapeutic use | Aged, 80 and over | Adult | Female | Sofosbuvir - adverse effects | Sofosbuvir - therapeutic use | Liver Cirrhosis - drug therapy | Liver Cirrhosis - etiology | Antiviral Agents - therapeutic use | Genotype | Heterocyclic Compounds, 4 or More Rings - adverse effects | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - adverse effects | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Viral Nonstructural Proteins - antagonists & inhibitors | Drug Combinations | Clinical trials | Usage | Genetic aspects | Research | Hepatitis C virus | Headache | Fatigue | Infections | Nausea | Patients | Ribavirin | Studies | Cirrhosis | Sleep disorders | Genotype & phenotype | Hepatitis | Hepatitis C | Drug therapy | Genotypes | Pharmaceuticals | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
18. Full Text Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
by Kowdley, Kris V and Gordon, Stuart C and Reddy, K. Rajender and Rossaro, Lorenzo and Bernstein, David E and Lawitz, Eric and Shiffman, Mitchell L and Schiff, Eugene and Ghalib, Reem and Ryan, Michael and Rustgi, Vinod and Chojkier, Mario and Herring, Robert and Di Bisceglie, Adrian M and Pockros, Paul J and Subramanian, G. Mani and An, Di and Svarovskaia, Evguenia and Hyland, Robert H and Pang, Phillip S and Symonds, William T and McHutchison, John G and Muir, Andrew J and Pound, David and Fried, Michael W and ION-3 Investigators
The New England Journal of Medicine, ISSN 0028-4793, 05/2014, Volume 370, Issue 20, pp. 1879 - 1888
In previously untreated patients with HCV genotype 1 infection without cirrhosis, the rate of sustained virologic response was 94% with 8 weeks of... 
NS5A INHIBITOR | MEDICINE, GENERAL & INTERNAL | CHRONIC HEPATITIS-C | Humans | Middle Aged | Drug Resistance, Viral | Fluorenes - therapeutic use | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | RNA, Viral - blood | Viral Load | Young Adult | Adult | Female | Fluorenes - adverse effects | Uridine Monophosphate - adverse effects | Benzimidazoles - adverse effects | Drug Therapy, Combination | Benzimidazoles - therapeutic use | Uridine Monophosphate - therapeutic use | Drug Administration Schedule | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Genotype | Hepatitis C, Chronic - drug therapy | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Aged | Sofosbuvir | Cirrhosis | Genotype & phenotype | Hepatitis | Mortality | Infections | Hepatitis C | Drug therapy | Patients | Ribavirin | Genotypes | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
19. Full Text Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data
: HEPATOLOGY, Vol. XX, No. X, 2015
by Wilder, Julius M and Jeffers, Lennox J and Ravendhran, Natarajan and Shiffman, Mitchell L and Poulos, John and Sulkowski, Mark S and Gitlin, Norman and Workowski, Kimberly and Zhu, Yanni and Yang, Jenny C and Pang, Phillip S and McHutchison, John G and Muir, Andrew J and Howell, Charles and Kowdley, Kris and Afdhal, Nezam and Reddy, K. Rajender
Hepatology, ISSN 0270-9139, 02/2016, Volume 63, Issue 2, pp. 437 - 444
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights